ReviewStroke research and treatment2025
Molecular Mechanism of MLC 901 in Acute Ischemic Stroke: A Review.
Review in Stroke research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Medical and Non-Surgical Strategies for Mild Traumatic Brain Injury.Korean journal of neurotrauma · 2026Review
- Poststroke anxiety and depression: epidemiology, mechanisms, and management strategies.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke is the leading cause of stroke all around the world. Ischemic stroke can cause severe and irreversible damage to the brain. Brain neuroprotection is a promising treatment strategy. Moleac (MLC) 901, a traditional Chinese medicine, is one alternative adjunctive therapy that enhances neuroprotection. The molecular mechanism of MLC 901 in reducing brain damage in stroke needs to be further explored. Therefore, a review was conducted. MLC 901 effectively improves cognitive function and aids in poststroke recovery by promoting neuroprotection and neuroplasticity in neurons that have suffered ischemic damage. It also increases blood supply to the brain. Studies have shown that MLC 901 operates through complex pathways, particularly by stimulating brain-derived neurotrophic factor (BDNF) expression, facilitating neurogenesis, promoting cell proliferation, and aiding in neuronal growth. These mechanisms collectively contribute to its neuroprotective effects by helping neurons survive, repairing brain tissue, and enhancing functional recovery after a stroke. Ischemic stroke induces a cascade leading to apoptosis. MLC 901 has neuroprotective and neuroplasticity effects by stimulating cell proliferation, synaptogenesis, and neuronal growth by various pathways, thereby inhibiting apoptosis and inflammation in acute ischemic stroke. MLC 901 reduces brain damage, improves motor function, and increases survival rate in acute ischemic stroke.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.